About Our Company
Halt Medical is focused on establishing a new standard of care for women with symptomatic uterine fibroids. A shocking 35 million women suffer from fibroids, 7 million are symptomatic, 2 million seek treatment and roughly 0.3 million get treated. Our Company has developed and launched the patented Acessa™ Procedure, using widely accepted, radiofrequency (RF) ablation to destroy uterine fibroids. The procedure is cleared by the FDA and has CE mark for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. The results of two U.S. and international trials, have proven safety, efficacy and durability. These data have generated 20 publications and three-year follow up.
Advancing minimally invasive, uterine-sparing solutions for women with symptomatic fibroids through innovative and easy-to-use technologies.
Women have more options.
Meet The Inventor Of Acessa™
As a board certified gynecologist with twenty nine years of clinical and research experience, Dr. Bruce Lee is credited for pioneering radiofrequency ablation of fibroids in women. In 2005, he cofounded Halt Medical, Inc. to design, manufacture, and commercialize new instrumentation specifically for the Acessa™ Procedure. While Chief Medical Officer, he worked with a dedicated team of engineers to design the Halt Fibroid Ablation System, oversaw phase 2 and phase 3 clinical trials, helped design the Acessa teaching methodology and authored multiple peer review articles. Since 2008, he has instructed new physicians on how to perform the procedure in Canada, Germany, Mexico, Guatemala and in hospitals and universities in 13 U.S. states. Dr. Lee has since treated four thousand fibroid tumors in over 500 patients. This work has helped establish two new Los Angeles-area medical centers dedicated exclusively to the life-changing treatment: the Center for Uterine Fibroid Treatment at Southern California Hospital at Culver City and Roxbury Surgical Associates in Beverly Hills, where he currently practices.
Kim Bridges - President & CEO
Halt, she served at Spectranetics [NYSE: SPNC], a global medical technology leader focusing on
cardiovascular solutions, as Senior Vice President of the Vascular Intervention division, which more
than doubled US revenue under her leadership. Prior to Spectranetics, Ms. Bridges held several global
vice president and management roles in sales, marketing and therapy development at companies such
as Blockade Medical, Stryker Neurovascular, Guidant Corporation and Johnson and Johnson. She
received her Executive MBA at the University of Southern California Marshall School of Business and
BS in Management from Pepperdine University.
Donald I. Galen, M.D., FACOG, - Medical Director
genetics and microbiology and attended USC School of Medicine. His four-year residency training
in obstetrics & gynecology was at UC Medical Center, San Francisco. Dr. Galen is certified by the
American Board of Obstetrics & Gynecology and by the Accreditation Council for Gynecologic
Endoscopy. He is also a member of the Society of Reproductive Surgeons and numerous other
professional organizations. Dr. Galen is renowned for his expertise in gynecologic microsurgery,
minimally invasive endoscopic surgery and Assisted Reproductive Technologies (ART). He is active
in didactic and hands-on surgical teaching.
Robert C. Skidmore - Senior Vice President of Operations & Manufacturing
and Medical Device Manufacturing companies. His medical manufacturing experience (Sunrise Tech,
Indigo Medical, Sanarus Medical) has been related to surgical, urology, dental and gynecology. He was
instrumental in establishing DFT/JIT technologies into a majority of the companies, substantially
reducing the overall cost of devices and capital equipment. Mr. Skidmore is a 2nd Degree Black Belt in
Kenpo Martial Arts, and he owns and operates a martial arts school in his hometown.
Rick K. Spero - Vice President of Research & Development
the past 19 years in the healthcare industry. His experience includes product design and project
management for high-volume disposables (Nellcor pulse oximeter sensors), lower-volume disposables
(Sanarus Cassi breast biopsy device) and capital equipment (Humphrey Instruments Ophthalmic Field
Analyzer and Retinal Analyzer). Mr. Spero has participated in multiple medical start-up companies. He
has been involved in numerous FDA submissions and is named as inventor or co-inventor on multiple
Jeremy McFadden - CFO
medical device and Healthcare IT industries. He has a public accounting background having received
his CPA while working for Deloitte and has combined this experience with a variety of corporate finance
roles at Philips Healthcare. Most recently, he was head of finance for the Philips Healthcare Informatics
business located in Foster City, CA.
Larry Anderson - Vice President of Sales
to women’s health. After spending 8 years with Ethicon Women’s Health and Urology, he entered the
start-up world with Interlace Medical, Inc. where his contributions directly contributed to the acquisition
by Hologic, Inc. Most recently, he served as a Kaiser Vertical Manager and District Sales Manager for
Hologic, Inc. Mr. Anderson is a 1997 graduate of the United States Military Academy at West Point with
a BS in Systems Engineering.
Tyler Holcomb - Director of Global Marketing
health, successfully introducing more than five new major platform technologies to the market.
Mr. Holcomb was instrumental in accelerating growth for venture-funded Interlace Medical, Inc.
(acquired by Hologic, Inc.), helping to build the initial market presence from scratch. Tyler graduated
with honors from the University of Iowa, where he was Captain of the Men's Swim Team, a 4-time Big Ten Championship Finalist and Olympic Trial Qualifier; awarded a full athletic scholarship.